ChromaDex Corporation Reports First Quarter 2024 Financial Results
ChromaDex (NASDAQ:CDXC) reported first quarter 2024 financial results with total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million, and positive Adjusted EBITDA of $0.7 million. The company reiterated a full-year outlook with net sales growth of at least 16%. Tru Niagen® contributed $17.4 million to total net sales, and ChromaDex expanded distribution through partnerships with The Vitamin Shoppe and Sprouts Farmers Market. Operating expenses decreased, net loss improved, and Adjusted EBITDA turned positive. The company aims for revenue growth, gross margin improvement, and increased investments in research and development, marketing, and product launches.
Total net sales of $22.2 million with a gross margin of 60.7% and a positive Adjusted EBITDA of $0.7 million for the first quarter of 2024.
Net loss improved to $0.5 million compared to $1.9 million in the first quarter of 2023.
ChromaDex strengthened its Tru Niagen® product portfolio through third-party verification and expanded distribution with The Vitamin Shoppe and Sprouts Farmers Market.
Operating expenses decreased by $1.3 million, while investments in research and development increased to support future launches.
The company plans to focus on revenue growth, gross margin improvement, and continued investment in R&D, marketing, and product launches for the full year 2024.
Total net sales decreased by 2% from the prior year quarter, primarily due to reduced Tru Niagen® sales through distributor partners.
Net cash inflow from operating activities decreased by $2.5 million due to reductions in accounts payable and lower reductions in inventory and prepaid expenses.
While gross margin percentage improved, the slight increase was primarily driven by changes in business mix.
Insights
Upon reviewing the financial metrics presented, ChromaDex Corporation displays a mixed financial picture for the first quarter of 2024. A key highlight is the positive Adjusted EBITDA of
However, investors should note the reduction in net cash inflow from operating activities, down to
The full-year outlook projecting revenue growth of at least
The announcement by ChromaDex Corporation regarding expanded distribution partnerships with The Vitamin Shoppe and Sprouts Farmers Market reveals a strategic maneuver to tap into the health-conscious consumer segment. The proliferation of Tru Niagen® in 700 specialty retail locations and 400 grocery chain stores presents a significant opportunity for increased market penetration and brand visibility.
Additionally, the third-party verification through the Alkemist Assured™ program lends credibility and trust to the quality of ChromaDex's offerings, potentially bolstering consumer confidence and driving sales. In the ever-expanding nutraceutical space, such differentiators can be critical in influencing consumer purchase decisions.
From a market perspective, it's essential to understand the timing of sales and the impact of distributor partnerships on revenue streams. For instance, the decline in total net sales by 2% primarily due to reduced sales through distributor partners raises questions about the effectiveness and stability of these channels. As the company intensifies efforts for new product launches, how they navigate these challenges will be consequential to their market position.
Total net sales of
First Quarter 2024 Financial and Recent Operational Highlights
-
Total net sales were
, with$22.2 million from Tru Niagen®.$17.4 million -
Solid gross margin of
60.7% , an increase of 80 basis points, compared to59.9% from the prior year quarter. -
Sales and marketing expense as a percentage of net sales was
30.4% , an improvement of 450 basis points, compared to34.9% from the prior year quarter. -
Total operating expenses decreased
while increasing investments in research and development initiatives.$1.3 million -
Net loss was
or$0.5 million per share, a$(0.01) improvement, or$1.4 million per share, from the prior year quarter.$0.02 -
Adjusted EBITDA, a non-GAAP measure, improved to a positive
from a negative$0.7 million in the prior year quarter.$0.1 million - In March 2024, the Tru Niagen® product portfolio(1) attained third-party verification through the Alkemist Assured™ testing transparency program conducted by Alkemist Labs, a distinguished third-party testing laboratory known for its rigorous analysis of herbal and dietary supplements. This verification reinforces ChromaDex's commitment to excellence by ensuring high-quality, safe ingredients and transparency.
-
In April 2024, ChromaDex expanded distribution of Tru Niagen®, announcing partnerships with The Vitamin Shoppe and Sprouts Farmers Market, both targeting health-conscious consumers. Tru Niagen® is now available in 700 The Vitamin Shoppe and Super Supplements specialty retail locations and online, as well as in 400 Sprouts Farmers Market locations, marking the inaugural launch with a major
U.S. grocery chain.
“During the first quarter of 2024, we delivered
(1) Excluding Tru Niagen Pro 1,000 mg, which is NSF Certified for Sport®.
Results of operations for the three months ended March 31, 2024 compared to the prior year quarter
ChromaDex recorded net sales of
Gross margin percentage improved 80 basis points to
Operating expense decreased
Net loss was
Net cash inflow from operating activities was
2024 Full Year Outlook
Looking forward, for the full year, the Company expects the trajectory of full year revenue growth to continue, projecting a higher rate of revenue growth than the prior year growth of
Investor Conference Call
A live webcast will be held Wednesday, May 8, 2024 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss ChromaDex’s first-quarter financial results and provide a general business update.
To listen to the webcast, or to view the earnings press release and its accompanying financial exhibits, please visit the Investors Relations section of ChromaDex’s website at http://chromadex.com. The toll-free dial-in information for this call is 1-888-596-4144 with Conference ID: 8584242.
The webcast will be recorded, and will be available for replay via the website from 7:30 p.m. Eastern time on May 8, 2024 through 11:59 p.m. Eastern time on May 15, 2024. The replay of the call can also be accessed by dialing 800-770-2030, using the Replay ID: 8584242.
Important Note on Forward Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes” “seeks,” “may,” “will,” “should,” “could,” “predicts,” “projects,” “continue,” “would” or the negative of such terms or other similar expressions. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the quotation from ChromaDex’s Chief Executive Officer, and statements related to the Company’s 2024 financial outlook including but not limited to revenue growth, gross margin, expenses, and investment plans. Risks that contribute to the uncertain nature of the forward-looking statements include: inflationary conditions and adverse economic conditions; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of conducting business in
About ChromaDex:
ChromaDex Corporation is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through supplementation with NAD+ precursors. ChromaDex is the innovator behind the NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio.
The Company delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen® available at www.TruNiagen.com and through partnerships with global retailers and distributors. The Company also develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Company further offers natural product fine chemicals, known as phytochemicals, and related research and development services. Follow us on X (formerly Twitter) @ChromaDex and Instagram @TruNiagen and subscribe to our latest news via our website accessible at www.ChromaDex.com to which ChromaDex regularly posts copies of its press releases as well as additional updates and financial information about the Company.
ChromaDex Corporation and Subsidiaries Unaudited Condensed Consolidated Statements of Operations |
|||||||
|
Three Months Ended March 31, |
||||||
|
|
2024 |
|
|
|
2023 |
|
(In thousands, except per share data) |
|
|
|
||||
Sales, net |
$ |
22,153 |
|
|
$ |
22,556 |
|
Cost of sales |
|
8,697 |
|
|
|
9,038 |
|
Gross profit |
|
13,456 |
|
|
|
13,518 |
|
Operating expenses: |
|
|
|
||||
Sales and marketing |
|
6,740 |
|
|
|
7,874 |
|
Research and development |
|
2,095 |
|
|
|
1,193 |
|
General and administrative |
|
5,352 |
|
|
|
6,419 |
|
Total operating expenses |
|
14,187 |
|
|
|
15,486 |
|
Operating loss |
|
(731 |
) |
|
|
(1,968 |
) |
|
|
|
|
||||
Nonoperating income: |
|
|
|
||||
Interest income, net |
|
239 |
|
|
|
66 |
|
Net loss |
$ |
(492 |
) |
|
$ |
(1,902 |
) |
|
|
|
|
||||
Basic and diluted loss per share attributable to common stockholders: |
$ |
(0.01 |
) |
|
$ |
(0.03 |
) |
Basic and diluted weighted average common shares outstanding |
|
75,230 |
|
|
|
74,796 |
|
ChromaDex Corporation and Subsidiaries Unaudited Condensed Consolidated Balance Sheets |
|||||
(In thousands except par values, unless otherwise indicated) |
March 31, 2024 |
|
December 31, 2023 |
||
Assets |
|
|
|
||
Current assets: |
|
|
|
||
Cash and cash equivalents, including restricted cash of |
$ |
27,565 |
|
$ |
27,325 |
Trade receivables, net of allowances of |
|
6,604 |
|
|
5,234 |
Inventories |
|
12,495 |
|
|
14,525 |
Prepaid expenses and other assets |
|
2,312 |
|
|
2,450 |
Total current assets |
|
48,976 |
|
|
49,534 |
|
|
|
|
||
Leasehold improvements and equipment, net |
|
2,000 |
|
|
2,137 |
Intangible assets, net |
|
472 |
|
|
510 |
Right-of-use assets |
|
2,226 |
|
|
2,400 |
Other long-term assets |
|
405 |
|
|
383 |
Total assets |
$ |
54,079 |
|
$ |
54,964 |
|
|
|
|
||
Liabilities and Stockholders' Equity |
|
|
|
||
Current liabilities: |
|
|
|
||
Accounts payable |
$ |
7,899 |
|
$ |
10,232 |
Accrued expenses |
|
10,465 |
|
|
9,493 |
Current maturities of operating lease obligations |
|
850 |
|
|
691 |
Current maturities of finance lease obligations |
|
11 |
|
|
11 |
Customer deposits |
|
227 |
|
|
195 |
Total current liabilities |
|
19,452 |
|
|
20,622 |
Deferred revenue |
|
3,311 |
|
|
3,311 |
Operating lease obligations, less current maturities |
|
2,356 |
|
|
2,563 |
Finance lease obligations, less current maturities |
|
9 |
|
|
12 |
Total stockholders’ equity |
|
28,951 |
|
|
28,456 |
Total liabilities and stockholders’ equity |
$ |
54,079 |
|
$ |
54,964 |
ChromaDex Corporation and Subsidiaries Unaudited Condensed Consolidated Statements of Cash Flows |
|||||||
|
Three Months Ended March 31, |
||||||
(In thousands) |
|
2024 |
|
|
|
2023 |
|
Net cash provided by / (used in): |
|
|
|
||||
Operating activities |
$ |
295 |
|
|
$ |
2,792 |
|
Investing activities |
|
(41 |
) |
|
|
(91 |
) |
Financing activities |
|
(14 |
) |
|
|
(1 |
) |
Net increase in cash and cash equivalents |
|
240 |
|
|
|
2,700 |
|
Cash and cash equivalents beginning of period |
|
27,325 |
|
|
|
20,441 |
|
Cash and cash equivalents at end of period |
$ |
27,565 |
|
|
$ |
23,141 |
|
ChromaDex Corporation and Subsidiaries Unaudited Reconciliation of Non-GAAP Financial Measures |
|||||||||||||||||||
Reconciliation of Net Income (Loss) to Adjusted EBITDA |
|||||||||||||||||||
(In thousands) |
Q1 2024 |
|
Q4 2023 |
|
Q3 2023 |
|
Q2 2023 |
|
Q1 2023 |
||||||||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Net income (loss), as reported |
$ |
(492 |
) |
|
$ |
114 |
|
|
$ |
(959 |
) |
|
$ |
(2,191 |
) |
|
$ |
(1,902 |
) |
Adjustments: |
|
|
|
|
|
|
|
|
|
||||||||||
Interest (income) expense, net |
|
(239 |
) |
|
|
(282 |
) |
|
|
(188 |
) |
|
|
(125 |
) |
|
|
(66 |
) |
Depreciation |
|
178 |
|
|
|
177 |
|
|
|
233 |
|
|
|
232 |
|
|
|
228 |
|
Amortization of intangibles |
|
38 |
|
|
|
39 |
|
|
|
39 |
|
|
|
39 |
|
|
|
41 |
|
Amortization of right of use assets |
|
174 |
|
|
|
157 |
|
|
|
176 |
|
|
|
173 |
|
|
|
171 |
|
Share-based compensation |
|
984 |
|
|
|
1,037 |
|
|
|
1,117 |
|
|
|
1,324 |
|
|
|
1,273 |
|
Severance and restructuring |
|
27 |
|
|
|
5 |
|
|
|
86 |
|
|
|
766 |
|
|
|
186 |
|
Adjusted EBITDA |
$ |
670 |
|
|
$ |
1,247 |
|
|
$ |
504 |
|
|
$ |
218 |
|
|
$ |
(69 |
) |
Non-GAAP Financial Information:
To supplement ChromaDex’s unaudited financial data presented in accordance with generally accepted accounting principles (GAAP), the Company has presented Adjusted EBITDA, a non-GAAP financial measure. ChromaDex believes the presentation of this non-GAAP financial measure provides important supplemental information to management and investors and enhances the overall understanding of the Company’s historical and current financial operating performance. The Company believes disclosure of the non-GAAP financial measure has substance because the excluded expenses are infrequent in nature, are variable in nature or do not represent current cash expenditures. Further, such non-GAAP financial measure is among the indicators the Company uses as a basis for evaluating the Company’s financial performance as well as for planning and forecasting purposes. Accordingly, disclosure of this non-GAAP financial measure provides investors with the same information that management uses to understand the Company’s economic performance year-over-year.
Adjusted EBITDA is defined as net income (loss) before (a) interest, (b) depreciation, (c) amortization, (d) non-cash share-based compensation costs and (e) severance and restructuring expense. While ChromaDex believes that this non-GAAP financial measure provides useful supplemental information to investors, there are limitations associated with the use of such measure. This measure is not prepared in accordance with GAAP and may not be directly comparable to similarly titled measures of other companies due to potential differences in the method of calculation. Management compensates for these limitations by relying primarily on the Company’s GAAP results and by using Adjusted EBITDA only supplementally and by reviewing the reconciliation of the non-GAAP financial measure to its most comparable GAAP financial measure.
Non-GAAP financial measures are not prepared in accordance with, or an alternative for, generally accepted accounting principles in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508747070/en/
Investor Relations
Ben Shamsian
Lytham Partners
+1 (646) 829-9701
Shamsian@LythamPartners.com
Media Relations
Kendall Knysch
Director of Media Relations
+1 (310) 388-6706 Ext. 689
Kendall.Knysch@ChromaDex.com
Source: ChromaDex Corporation
FAQ
What were ChromaDex's total net sales for the first quarter of 2024?
What was the gross margin percentage for ChromaDex in the first quarter of 2024?
What was the net loss for ChromaDex in the first quarter of 2024?
What is the stock symbol for ChromaDex?